Stay updated with breaking news from Combination Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
2023 Fourth-Quarter reported sales growth of 7.3% to $21.4 Billion with operational growth of 7.2%* and adjusted operational growth of 5.7%*. Operational growth excluding COVID-19 Vaccine of...
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2023 Financial Results Conference Call. All participants are presently in listen-only mode.
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx First Quarter 2023 Financial Results Conference Call.
04.08.2022 - – Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key Secondary Endpoints – – Encouraging Preliminary Data from Phase 1/2 Study Evaluating Nirogacestat in Combination with ...
Investegate announcements from Faron Pharma. Oy, First Patient Dosed in Ph I/II BEXMAB Combo Study